KYNB · XBRL financial data

Kyntra Bio financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (KYNB's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	—	year only	—	—	—	year only	—	—	—	year only	—	—
Revenue from contracts with customers	40	27*	56	51	46	year only	3	1	1	1*	4	(1)
Cost of revenue	4	5*	26	5	5	(21)*	0	0	(0)	0*	4	0
Research and development	61	52*	38	34	22	1*	9	6	1	7*	8	7
Selling, general and administrative	26	24*	23	22	18	(13)*	8	7	5	7*	6	9
Operating income (loss)	(63)	(54)*	(31)	(11)	(17)	(92)*	(15)	(12)	(5)	(14)*	(14)	(18)
Interest expense	5	5*	5	5	5	(7)*	2	2	2	2*	2	2
Income tax expense (benefit)	0	0*	0	(0)	0	(0)*	0	(0)	0	0*	0	(0)
Net income (loss)	(64)	(56)*	(33)	(16)	(17)	18*	5	(8)	201	(14)*	(15)	12
Earnings per share, basic USD per share	(0.65)	(0.57)*	(0.33)	(0.16)	(0.17)	0.18*	0.05	(1.88)	49.61	—	(3.76)	2.96
Earnings per share, diluted USD per share	(0.65)	(0.57)*	(0.33)	(0.16)	(0.17)	0.18*	0.05	(1.88)	49.61	—	(3.76)	2.96
Weighted average shares, basic millions of shares	98	98*	99	100	101	101*	101	4	4	—	4	4
Weighted average shares, diluted millions of shares	98	98*	99	100	101	101*	101	4	4	—	4	4

† Share count changed about 1/25 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (KYNB's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	121	114	106	141	131	50	34	23	118	48	37	51
Short-term investments	130	122	72	0	0	0	—	—	—	41	50	41
Accounts receivable	32	13	37	6	29	0	0	0	0	0	5	0
Inventory	41	42	27	25	24	3	3	4	4	4	3	3
Prepaid and other current assets	40	42	36	37	61	32	3	2	11	6	6	2
Total current assets	364	332	278	209	245	197	149	162	133	99	101	97
Property and equipment, net	15	13	12	11	8	0	—	—	—	—	—	—
Right-of-use asset	71	68	65	61	2	0	—	—	—	—	—	—
Total assets	460	424	366	293	264	215	165	178	137	120	110	101
Accounts payable	19	18	4	10	9	5	7	10	5	4	5	8
Accrued liabilities	171	173	164	114	151	62	35	36	26	20	17	23
Total current liabilities	209	218	197	149	191	133	73	156	36	29	28	36
Lease liability, non-current	70	67	63	58	1	0	—	—	—	—	—	—
Total liabilities	576	586	552	484	466	398	340	359	120	115	119	109
Accumulated deficit	(1,786)	(1,842)	(1,875)	(1,890)	(1,907)	(1,889)	(1,885)	(1,892)	(1,692)	(1,706)	(1,721)	(1,709)
Total stockholders' equity	(157)	(204)	(228)	(232)	(244)	(226)	(217)	(223)	(17)	(30)	(44)	(30)
Total liabilities and equity	460	424	366	293	264	215	165	178	137	120	110	101
Common shares outstanding (cover page) millions of shares	98	99	99	100	101	101	101	4	4	4	4	4

† Share count changed about 1/25 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (KYNB's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(64)	(56)*	(33)	(16)	(17)	18*	5	(8)	201	(14)*	(15)	12
Stock-based compensation	9*	9*	9	9*	8*	0*	3	2*	1*	1*	1	1*
Net cash from operating activities	(85)*	(18)*	(59)	(40)*	(8)*	(30)*	3	13*	(2)*	(18)*	(14)	(4)*
Purchases of property and equipment	1*	0*	0	0*	0*	0*	0	0*	0*	0*	0	0*
Net cash from investing activities	54*	10*	51	72*	1*	2*	(0)	(0)*	87*	(52)*	3	18*
Proceeds from issuing common stock	0*	0*	0	0*	0*	0*	—	—	0*	0*	—	—
Net cash from financing activities	(0)*	(0)*	(0)	0*	(0)*	0*	(0)	(0)*	(86)*	(0)*	(0)	(0)*
Net change in cash	(32)*	(7)*	(8)	35*	(10)*	(29)*	4	14*	(2)*	(70)*	(11)	14*

† Share count changed about 1/25 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Fibrogen	51	(1.5)	(4)*	4.0M	22.9 quarters	Q2 FY26 10-QJun 30, 2026
Armata Pharmaceuticals	24	not reported	(8.7)*	37.2M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Imunon	6.9	not reported	(3)*	5.6M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
Lunai Bioworks	1.7	0*	(1.8)*	5.0M	0.9 quarters	Q4 FY26 10-KJun 30, 2026
Dare Bioscience	13	0.2	(6.8)*	15.3M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Aptose Biosciences	1	not reported	(5.8)	2.6M	0.2 quarters	Q1 FY26 10-QMar 31, 2026
Ovid Therapeutics	11	0.7	(18)*	195.3M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
vTv Therapeutics	87	0	(11)*	not reported	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Marimed	8.4	42	2.2*	403.0M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.